What the FDA labels say about taking them together
Dexamethasone and lenalidomide
Dexamethasone's FDA label (Hemady) of January 9, 2026 names lenalidomide in its warnings and precautions section, and lenalidomide's label names dexamethasone too. The lenalidomide label: “… stroke in patients with multiple myeloma who were treated with REVLIMID and dexamethasone therapy.”
Check it at the source: the dexamethasone FDA label on DailyMed (effective June 6, 2025, Hikma Pharmaceuticals USA, Inc.); the lenalidomide FDA label on DailyMed (effective March 24, 2023, Celgene Corporation).
What does the dexamethasone label say about lenalidomide?
Hemady label (Edenbridge Pharmaceuticals LLC., January 9, 2026), warnings and precautionsThe risk for venous and arterial thromboembolism increases significantly when dexamethasone is administered with anti-myeloma products (e.g., thalidomide, lenalidomide, pomalidomide, and carfilzomib).
Source: FDA drug label (Hemady, NDA211379), Edenbridge Pharmaceuticals LLC., effective January 9, 2026 (SPL set 6b9cf32c-6d60-4853-bbfd-2304ffc2c129), via openFDA
Source: FDA drug label (Dexamethasone Intensol), Hikma Pharmaceuticals USA, Inc., effective June 6, 2025 (SPL set b15200fb-1826-472b-a907-e677a272513b), via openFDA; the full label on DailyMed
What does the lenalidomide label say about dexamethasone?
Lenalidomide label, boxed warningVenous and Arterial Thromboembolism REVLIMID has demonstrated a significantly increased risk of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as risk of myocardial infarction and stroke in patients with multiple myeloma who were treated with REVLIMID and dexamethasone therapy.
Lenalidomide label, drug interactionsIt is not known whether there is an interaction between dexamethasone and warfarin.
Lenalidomide label, warnings and precautionsIncreased Mortality: Observed in patients with MM when pembrolizumab was added to dexamethasone and a thalidomide analogue ( 5.7 ).
Source: FDA drug label (Revlimid), NDA021880 (Bristol Myers Squibb), as published by Celgene Corporation, effective March 24, 2023 (SPL set 5fa97bf5-28a2-48f1-8955-f56012d296be), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Dexamethasone | Lenalidomide | |
|---|---|---|
| Labeled for | Asthma, Eczema (atopic dermatitis), Leukemia, lymphoma and myeloma, Herpes and shingles, Crohn's disease and ulcerative colitis, Multiple sclerosis, Osteoarthritis, Rheumatoid arthritis, Psoriasis, Allergies, Anemia, Pain | Leukemia, lymphoma and myeloma, Anemia |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.193 per tablet 4 mg tablet | n/a |
| Shortage now | In shortage | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once